NeuroSense Therapeutics Faces Nasdaq Delisting Warning
Ticker: NRSNW · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1875091
Sentiment: bearish
Topics: delisting-risk, compliance, nasdaq
TL;DR
Nasdaq says NeuroSense needs $2.5M equity or it's off the exchange. They're fighting it.
AI Summary
NeuroSense Therapeutics Ltd. received a written notice from Nasdaq on June 21, 2024, stating it had not regained compliance with the minimum stockholders' equity requirement of $2.5 million. The company has requested a hearing before the Nasdaq Hearings Panel to address this non-compliance.
Why It Matters
Failure to regain compliance could lead to the delisting of NeuroSense Therapeutics' shares from the Nasdaq, impacting liquidity and investor confidence.
Risk Assessment
Risk Level: medium — The company is at risk of being delisted from Nasdaq due to not meeting minimum stockholders' equity requirements.
Key Numbers
- $2.5 million — Minimum Stockholders' Equity (This is the threshold NeuroSense Therapeutics failed to meet, leading to the Nasdaq non-compliance notice.)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — The company filing the report and receiving the Nasdaq notice.
- Nasdaq (company) — The stock exchange that issued the non-compliance notice.
- $2.5 million (dollar_amount) — The minimum stockholders' equity required by Nasdaq.
- June 21, 2024 (date) — The date NeuroSense Therapeutics received the written notice from Nasdaq.
FAQ
What specific Nasdaq Listing Rule did NeuroSense Therapeutics fail to comply with?
NeuroSense Therapeutics failed to comply with Nasdaq Listing Rule 5550(b), which requires a minimum stockholders' equity of $2.5 million.
When did NeuroSense Therapeutics receive the notice from Nasdaq?
The company received the written notice from Nasdaq on June 21, 2024.
What action has NeuroSense Therapeutics taken in response to the Nasdaq notice?
NeuroSense Therapeutics has requested a hearing before the Nasdaq Hearings Panel.
What is the minimum stockholders' equity required by Nasdaq for continued listing?
The minimum stockholders' equity required by Nasdaq is $2.5 million.
What form is this SEC filing?
This SEC filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 1,293 words · 5 min read · ~4 pages · Grade level 17.3 · Accepted 2024-12-17 14:42:20
Key Financial Figures
- $2.5 million — a minimum stockholders’ equity of $2.5 million (the “Equity Rule”). The Co
- $3.0 million — he date of this filing is approximately $3.0 million. The increase in the Company’s st
- $2.8 million — ry Warrants”) against payment for $2.8 million with the remaining payment made on Dece
- $5 million — total gross proceeds to the Company of $5 million. This transaction had the effect of inc
- $4.93 million — eholders’ equity by approximately $4.93 million (for additional details on this transac
- $1.3 million — eholders’ equity by approximately $1.3 million. On August 16, 2024, the Company ente
- $2,524,437 — ng an aggregate offering price of up to $2,524,437. To date, the Company has issued 1,105,
- $1.2 million — shares for aggregate gross proceeds of $1.2 million. This transaction has had the effect of
- $1.15 million — eholders’ equity by approximately $1.15 million (for additional details on this transac
- $600,000 — 0 ordinary shares for gross proceeds of $600,000. This transaction has had the effect of
- $585,000 — eholders’ equity by approximately $585,000 (for additional details on this transac
Filing Documents
- ea0225129-6k_neuro.htm (6-K) — 24KB
- 0001213900-24-109699.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: December 17, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3